-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gilead recently reported third-quarter 2020 revenue of $6.5 billion, up 17 percent from $5.5 billion a year earlier, above analysts' expectations of $6.3 billion. The FDA-approved first anti-new crown drug, Redsyvir, generated $873 million (about $5.8 billion at the latest exchange rate), and Gilead made clear that revenue growth for the quarter was primarily due to higher sales of Redsyvir and core HIV drugs.
sales figures for redsiwe were the highest in the U.S., at $785 million, followed by Europe at $0.6 billion and other regions at $228 million.
Although Redsiway has obtained varying degrees of approval or authorization to treat new coronary pneumonia in more than 50 countries with prior research data, including emergency use permits in Japan and conditional listing permits in the European Union, Redsiway's sales in overseas markets outside the United States have not been fully opened.
One of the constraints behind this could be capacity, according to E-Drug managers, after US media reported that Gilead was focusing its sales on the US mainland and actively marketing Redsyway to DOCTORS in the US.
also limited to capacity, and until the third quarter Redsiwell was only able to supply outside the U.S. on a fairly limited basis.
said in August that it planned to produce more than 2 million treatments by the end of the year and that it expected to "add millions more" by 2021.
's plans to increase production are progressing steadily, Gilead CEO Daniel O'Day said on an October 28 investor conference call, "Thanks to efforts since January to increase supply, we are now able to meet global demand."
" however, Gilead also noted that Redseave's sales were highly volatile and uncertain due to the impact of the global health environment.
Despite a surge in new crown cases in the U.S. summer, many of them young people, hospitalization rates actually fell, and by the end of the third quarter they had fallen to about 5%, so Gilead lowered the upper limit of its earnings guidance range and expects full-year adjusted EPS (earnings per share) to be between $6.25-$6.60, previously expected $6.25-$7.65, and full-year revenue of $23-23.5 billion, from $23-25 billion previously forecast.
October 22nd, EST, the FDA officially approved Redsiway's listing for COVID-19 treatment for adults and children 12 years of age and older who weigh at least 40 kg and require hospitalization, which is currently the only FDA-approved COVID-19 therapy in the United States.
In addition, according to Gilead's june prices in developed countries such as the United States, a course of treatment at Rydersiwe costs between $2,340 (about 16,000 yuan) and $3,120 (about 21,000 yuan), depending on the country and the type of insurance.
, the FDA's approval contradicts the World Health Organization's findings.
At a regular WHO briefing on 16 October on new coronary pneumonia, WHO Director-General Tan Desser said the interim results of the Solidarity Trials showed that Redsivir, hydroxychloroquine, Lopinavir/Litonave and interferon therapy appeared to have little effect on the 28-day mortality rate or the course of hospitalization in hospitalized patients.
WHO trials showed that Redsywee had little effect in severe cases, with 301 deaths among 2,743 severe patients in the Redsiway group and 303 deaths among 2,708 severe patients in the control group;
later issued a statement questioning the reliability of the design and conclusions, saying the WTO had not "tested with the strictest scientific standards."
WHO has announced that it will publish official guidelines for the treatment of the new crown after another team within the United Nations health agency reviews the study data, which is expected to be published within three to four weeks.
source: Medical Valley.com Copyright Notice: All text, images and audio and video materials that indicate "Source: Mets Medicine" or "Source: MedSci Originals" on this website are owned by Mets Medical and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here